Annexes to the interim recommendations for use of theChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™)
15 March 2022
| COVID-19: Vaccines
Overview
These are the annexes to WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19. Annexes 1–6 contain tables that summarize the grading of recommendations, assessment, development and evaluations (GRADE). Annexes 7–9 contain the SAGE evidence-to-recommendation framework tables (ETR tables).
GRADE and ETR tables are updated as recommendations are updated.
This document has been updated: version 15 March 2022.
Related documents:
Archived versions:
- Annexes to the interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience). Version 30 July 2021
- Annexes to the interim
recommendations for use of the ChAdOx1-S [recombinant] vaccine against
COVID-19 (AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK
Bioscience). Version 21 April 2021
WHO Team
Immunization, Vaccines and Biologicals (IVB),
Strategic Advisory Group of Experts on Immunization,
WHO Headquarters (HQ) OLD
Number of pages
34
Reference numbers
WHO Reference Number: WHO/2019-nCoV/vaccines/SAGE_recommendation/AZD1222/annexes/2021.3
Copyright
